Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
International Cancer Conference Journal|April 3, 2026
Exploratory case series of conversion to carbon ion radiotherapy after systemic therapy in advanced hepatocellular carcinomaHaruka Anzai, Chihiro Miwa, Sadahisa Ogasawara, et al.
Liver Cancer|March 27, 2025
Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic TherapyMasanori Inoue, Sadahisa Ogasawara, Kazufumi Kobayashi, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 1, 2022
A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosisTakafumi Sakuma, Masato Nakamura, Tetsuhiro Chiba, et al.
JHEP Reports : Innovation in Hepatology|March 29, 2026
MVI-targeted carbon-ion radiotherapy combined with immunotherapy for advanced hepatocellular carcinoma: Phase Ib DEPARTURE trialSadahisa Ogasawara, Keisuke Koroki, Hirokazu Makishima, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 29, 2024
Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage-associated molecular pattern analysisTomomi Ozaki, Sae Yumita, Sadahisa Ogasawara, et al.
Drugs - Real World Outcomes|July 19, 2023
Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective AnalysisHiroaki Kanzaki, Sadahisa Ogasawara, Tomomi Okubo, et al.
Liver Cancer|October 21, 2020
Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical TrialsKeisuke Koroki, Sadahisa Ogasawara, Yoshihiko Ooka, et al.
BMJ Open|April 9, 2022
Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trialSadahisa Ogasawara, Keisuke Koroki, Hirokazu Makishima, et al.
Scientific Reports|March 6, 2021
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinomaHiroaki Kanzaki, Tetsuhiro Chiba, Junjie Ao, et al.
JHEP Reports : Innovation in Hepatology|December 9, 2025
The efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in relation to tumor-infiltrating lymphocytesHiroaki Kanzaki, Takamasa Ishino, Sadahisa Ogasawara, et al.
Pageof 5